Trastuzumab [Herceptin] has received extended approval for the treatment of localised breast cancer in Australia

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1544, 2006-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cardiac safety of trastuzumab in the treatment of breast cancer

By Chien A Jo   Rugo Hope S  

Expert Opinion on Drug Safety, Vol. 9, Iss. 2, 2010-03 ,pp. : 335-346

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer

By Nabholtz Jean-marc   Gligorov Joseph  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1555-1564

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair   Millward Michael J.  

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing

By Simoens Steven  

PharmacoEconomics, Vol. 26, Iss. 10, 2008-01 ,pp. : 807-809

Adis International

Access to resources Recommend Favorite

High hopes for Herceptin in inflammatory breast cancer

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite